SciClone (SCLN) Issues Strong FY11, FY12 Revs Update

FREE Breaking News Alerts from StreetInsider.com!

SCLN Hot Sheet

Revenue Growth %: +80.6%

Financial Fact:
Total revenues: 39.16M

Today's EPS Names:
TARO, BRLI, TLB, More

SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced its anticipated full-year 2011 revenues and year-end cash position, and provided its 2012 initial revenue and year-end cash guidance as follows:

For 2011, the Company anticipates revenues of approximately $134 million (unaudited) including revenues of NovaMed Pharmaceuticals, Inc. (NovaMed) following the acquisition in April 2011, a 57% increase over 2010. The Street sees revs of $132.6 million.
Cash and investments are anticipated to be approximately $66 million (unaudited) at December 31, 2011, compared with $57 million at December 31, 2010. During 2011 the Company used cash of approximately $25 million (unaudited) for the acquisition of NovaMed and approximately $4 million (unaudited) for repurchases of Company Stock.
The Company anticipates 2012 sales revenue of $165 to $170 million, approximately a 25% increase over 2011. The Street is modeling $165.6 million.
The Company anticipates 2012 year-end cash and investments balances to be greater than $85 million excluding any impacts on cash balances associated with the Company's acquisition of new products and ongoing stock repurchase program.

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!